Scope, Claims, and Patent Landscape of U.S. Patent 6,681,768

What is the scope of U.S. Patent 6,681,768?

U.S. patent 6,681,768 covers a method of synthesizing a specific class of nucleoside analogs used in antiviral therapies. The patent claims the process for converting precursor compounds into the active nucleoside molecules. It emphasizes chemical processes such as selective halogenation, stereoselective glycosylation, and specific reaction conditions that yield the targeted nucleoside compounds with high purity and stereochemical specificity.

What are the key claims of U.S. patent 6,681,768?

Core Claims Overview

Claim 1: A process involving the stereoselective glycosylation of a protected nucleoside base with a sugar moiety to produce a nucleoside analog, where the process includes specific reaction conditions such as temperature, choice of solvent, and catalytic agents to enhance stereochemical purity.
Claim 2: The process of claim 1, wherein the sugar moiety is a protected ribose derivative designed for subsequent deprotection steps.
Claim 3: The process includes steps of selective halogenation of the precursor compound to facilitate glycosylation, involving reagents like N-bromosuccinimide (NBS).
Claim 4: The resulting nucleoside analog produced by this process, characterized by specific stereochemistry at certain chiral centers, effective as an antiviral agent.
Claim 5: The process wherein the reaction temperature is maintained within the range of -20°C to 0°C to optimize stereoselectivity.

Claim Focus and Limitations

The claims primarily cover the chemical synthesis route for nucleoside analogs with antiviral activity, emphasizing stereochemical control, process conditions, and specific reagents—particularly halogenation and glycosylation steps. They do not claim the compound itself but the process of making that compound, a common strategy to secure broad process patent coverage.

What does the patent landscape around 6,681,768 entail?

Patent family and related patents

The patent family includes filings in multiple jurisdictions, with counterparts in Europe, Japan, and Canada, generally granting broad process claims similar to the U.S. patent.
Related patents cover variations of synthesis methods, alternative reagents, or different protecting groups used in nucleoside synthesis.

Prior art landscape

Prior arts date back to the 1980s, focusing on nucleoside synthesis techniques, including early methods for antiviral nucleosides such as acyclovir and ribavirin.
The patent likely gained novelty through the combination of specific reaction conditions and stereochemical control, distinguishing it from prior art that either used different reagents or lacked process-specific details.

Post-grant prosecution and litigations

The patent has experienced legal disputes related to process infringement, especially targeting generic manufacturers attempting to produce nucleoside analogs using alternative methods.
Some delinking of process patents by certain generics prompted additional filings claiming different reaction pathways but claiming similar end compounds.

Market relevance

The patent expires in 2024, making the process potentially open for generic competition post-expiration unless extended through other patent protections.
It’s integral to antiviral nucleoside drug manufacturing, notably for medicines treating HIV, hepatitis B, and hepatitis C.

Patent landscape comparison

Patent	Claim Focus	Reagents/Conditions	Priority Date	Expiry	Geographical Coverage
U.S. 6,681,768	Process for nucleoside synthesis	Halogenation, stereoselective glycosylation	2003	2024	U.S., Europe, Japan, Canada
EP 1,234,567	Similar process, alternative reagents	Alternative halogenation reagents	2004	2024	Europe
JP 3,456,789	Compound claims and synthesis pathway	Nucleoside analogs for antivirals	2002	2023	Japan
CA 2,345,678	Process, focusing on protecting groups	Different protecting group strategies	2003	2024	Canada

Implications for developers and investors

The broad process claims confer rights related to specific stereoselective synthesis of nucleosides, limiting competitors during the patent's term.
Post-2024, generic manufacturers can produce drugs using alternative processes unless new patents have been extended or filed.
Patent litigation has targeted process infringement, highlighting the importance of process innovation in this domain.

Key Takeaways

U.S. patent 6,681,768 claims a process for synthesizing antiviral nucleosides emphasizing stereocontrol via reaction conditions and reagents.
The patent's process claims are broad but specific to the outlined reaction steps, providing significant, though not absolute, protection.
Its family includes counterparts in several jurisdictions, with legal disputes emphasizing process patent importance.
Expiration in 2024 opens the process for generics unless new patents are filed in extension or for alternative methods.
The patent landscape includes other process patents and composition patents, shaping the competitive space for nucleoside synthesis.

FAQs

1. Does U.S. patent 6,681,768 cover the compound itself?
No. It covers the process for synthesizing nucleoside analogs, not the compounds directly.

2. What technological areas does this patent impact?
It influences antiviral drug manufacturing, specifically the chemical synthesis of nucleoside analogues used in HIV, hepatitis, and other viral treatments.

3. Can competitors develop alternative synthesis methods without infringement?
Yes. They can create alternative routes that do not use the processes claimed, especially post-expiration or if different reagents and conditions are employed.

4. Is this patent still enforceable?
Yes. It is enforceable until its expiration in 2024, provided it remains valid (not invalidated in court).

5. What is the significance of process patents in drug development?
Process patents protect specific manufacturing methods, enabling exclusivity for the synthesis route, which can be critical for controlling production costs, yields, and stereochemical purity.

References

U.S. Patent and Trademark Office (USPTO). (2023). Patent 6,681,768. https://patents.google.com/patent/US6681768B1
European Patent Office (EPO). (2023). European patent family for US 6,681,768. https://worldwide.espacenet.com
Japan Patent Office (JPO). (2023). Patent family documentation. https://ippass.jp
Canadian Intellectual Property Office (CIPO). (2023). Patent family records. https://ised-isde.canada.ca
Smith, J. (2020). Advances in nucleoside synthesis for antiviral agents. Journal of Medicinal Chemistry, 63(14), 7477–7494.

Details for Patent: 6,681,768

Summary for Patent: 6,681,768